Taysha Gene Therapies (NASDAQ:TSHA) Insider Sukumar Nagendran Sells 26,918 Shares

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) insider Sukumar Nagendran sold 26,918 shares of the business’s stock in a transaction that occurred on Monday, January 26th. The stock was sold at an average price of $4.61, for a total value of $124,091.98. Following the sale, the insider owned 1,317,389 shares of the company’s stock, valued at approximately $6,073,163.29. This trade represents a 2.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Sukumar Nagendran also recently made the following trade(s):

• On Friday, January 23rd, Sukumar Nagendran sold 89,132 shares of Taysha Gene Therapies stock. The shares were sold at an average price of $4.75, for a total value of $423,377.00.
• On Monday, January 12th, Sukumar Nagendran sold 200,000 shares of Taysha Gene Therapies stock. The stock was sold at an average price of $4.71, for a total value of $942,000.00.
• On Friday, November 28th, Sukumar Nagendran sold 110,125 shares of Taysha Gene Therapies stock. The shares were sold at an average price of $4.75, for a total value of $523,093.75.
• On Monday, December 1st, Sukumar Nagendran sold 260,047 shares of Taysha Gene Therapies stock. The stock was sold at an average price of $4.51, for a total transaction of $1,172,811.97.

Taysha Gene Therapies Price Performance

Taysha Gene Therapies stock opened at $4.76 on Wednesday. The company has a fifty day simple moving average of $5.09 and a 200-day simple moving average of $4.08. The firm has a market capitalization of $1.30 billion, a price-to-earnings ratio of -14.42 and a beta of 1.02. The company has a quick ratio of 10.48, a current ratio of 10.48 and a debt-to-equity ratio of 0.23. Taysha Gene Therapies, Inc. has a 52-week low of $1.05 and a 52-week high of $6.02.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its quarterly earnings results on Tuesday, November 4th. The company reported ($0.09) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.09). Taysha Gene Therapies had a negative net margin of 1,144.97% and a negative return on equity of 67.26%. On average, equities analysts anticipate that Taysha Gene Therapies, Inc. will post -0.35 EPS for the current fiscal year.

Hedge Funds Weigh In On Taysha Gene Therapies

Hedge funds have recently made changes to their positions in the stock. Marex Group plc acquired a new stake in Taysha Gene Therapies in the 2nd quarter valued at approximately $29,000. E Fund Management Co. Ltd. purchased a new position in shares of Taysha Gene Therapies during the second quarter worth $31,000. ST Germain D J Co. Inc. grew its stake in shares of Taysha Gene Therapies by 81.8% in the third quarter. ST Germain D J Co. Inc. now owns 9,633 shares of the company’s stock valued at $32,000 after buying an additional 4,333 shares in the last quarter. May Hill Capital LLC purchased a new stake in shares of Taysha Gene Therapies in the 2nd quarter valued at $37,000. Finally, Arrowpoint Investment Partners Singapore Pte. Ltd. acquired a new position in Taysha Gene Therapies during the 3rd quarter worth about $40,000. Hedge funds and other institutional investors own 77.70% of the company’s stock.

Analyst Ratings Changes

Several analysts have issued reports on the company. JMP Securities set a $8.00 target price on Taysha Gene Therapies in a report on Wednesday, November 5th. The Goldman Sachs Group set a $11.00 price objective on shares of Taysha Gene Therapies in a research report on Thursday, December 4th. UBS Group set a $11.00 target price on shares of Taysha Gene Therapies in a report on Thursday, December 4th. Wall Street Zen lowered shares of Taysha Gene Therapies from a “hold” rating to a “sell” rating in a research report on Saturday, January 3rd. Finally, Chardan Capital reiterated a “buy” rating and issued a $12.00 price objective on shares of Taysha Gene Therapies in a research report on Tuesday, January 6th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $10.67.

Key Stories Impacting Taysha Gene Therapies

Here are the key news stories impacting Taysha Gene Therapies this week:

• Negative Sentiment: CFO Kamran Alam sold 78,968 shares on Jan. 23 at ~$4.75 and 23,849 shares on Jan. 26 at ~$4.61 (total ≈102,817 shares, ≈$485k). This reduced his stake by about 5.11% and 1.62% in the respective filings. CFO Form 4
• Negative Sentiment: CEO Sean P. Nolan sold 136,789 shares on Jan. 23 at ~$4.75 and 41,312 shares on Jan. 26 at ~$4.61 (total ≈178,101 shares, ≈$840k). These sales reduced his ownership by ~4.43% and ~1.40% in the respective filings. CEO Form 4
• Negative Sentiment: Insider Sukumar Nagendran sold 89,132 shares on Jan. 23 at ~$4.75 and 26,918 shares on Jan. 26 at ~$4.61 (total ≈116,050 shares, ≈$547k), reducing his stake by ~6.22% and ~2.00% in the respective filings. Director Form 4

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.